A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 468 participants.
Also called NCT04255238
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 468 participants
- Sponsor
- LG Chem
- Registry
-
NCT04255238
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04255238. Randomized; double masking; primary purpose treatment. Start 2020-06-30 (anticipated); primary completion 2022-05-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Gemigliptin 50mg
- Intervention (Drug)
- Dapagliflozin 10mg
- Lead sponsor
- LG Chem
Record details
- Record id
cardio:ct-nct04255238- Content hash
fcf877d0e369954115a9a8b659849de11a578c3441ad71e1a6b055cdfc38dfed